Literature DB >> 1652755

Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product.

U Santhanam1, A Ray, P B Sehgal.   

Abstract

The aberrant overexpression of interleukin 6 (IL-6) is implicated as an autocrine mechanism in the enhanced proliferation of the neoplastic cell elements in various B- and T-cell malignancies and in some carcinomas and sarcomas; many of these neoplasms have been shown to be associated with a mutated p53 gene. The possibility that wild-type (wt) p53, a nuclear tumor-suppressor protein, but not its transforming mutants might serve to repress IL-6 gene expression was investigated in HeLa cells. We transiently cotransfected these cells with constitutive cytomegalovirus (CMV) enhancer/promoter expression plasmids overproducing wt or mutant human or murine p53 and with appropriate chloramphenicol acetyltransferase (CAT) reporter plasmids containing the promoter elements of human IL-6, c-fos, or beta-actin genes or of porcine major histocompatibility complex (MHC) class I gene in pN-38 to evaluate the effect of the various p53 species on these promoters. Murine and human wt p53 derived from pCMVNc9 and pC53-SN3, respectively, strongly repressed the IL-6 (promoter position -225 to +13), c-fos (-711 to +42), beta-actin (-3400 to +912), and MHC (-528 to -38) promoters in serum-induced HeLa cells; additionally, IL-6 promoter/CAT transcription unit constructs induced by IL-1, phorbol ester, or pseudorabies virus were also repressed by wt human and murine p53. The murine transforming mutant p53 (pCMVc5) was less active in repressing the IL-6, c-fos, beta-actin, and MHC promoter constructs. The human p53 mutant derived from pC53-SCX3 was also less active than the wt protein in repressing the IL-6, c-fos, beta-actin, and MHC promoters, except that serum-induced IL-6/CAT expression was equally repressed by both human wt and mutant p53. In similar transient transfection experiments in HeLa cells, overexpression of the wt human retinoblastoma susceptibility gene product, RB, was found to repress the serum-induced IL-6 (-225 to +13), c-fos (-711 to +42), and beta-actin (-3400 to +912) promoters but not the PRV-induced IL-6 (-110 to +13) or the serum-induced MHC (-528 to -38) promoters. These observations identify transcriptional repression as a property of p53 and suggest that p53 and RB may be involved as transcriptional repressors in modulating IL-6 gene expression during cellular differentiation and oncogenesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1652755      PMCID: PMC52350          DOI: 10.1073/pnas.88.17.7605

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.

Authors:  L Raycroft; H Y Wu; G Lozano
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

2.  Interleukin-6 immunoreactivity in human tumors.

Authors:  S S Tabibzadeh; D Poubouridis; L T May; P B Sehgal
Journal:  Am J Pathol       Date:  1989-09       Impact factor: 4.307

3.  Negative regulation of human c-fos expression by the retinoblastoma gene product.

Authors:  P D Robbins; J M Horowitz; R C Mulligan
Journal:  Nature       Date:  1990-08-16       Impact factor: 49.962

4.  Molecular cloning and characterization of mutant and wild-type human beta-actin genes.

Authors:  J Leavitt; P Gunning; P Porreca; S Y Ng; C S Lin; L Kedes
Journal:  Mol Cell Biol       Date:  1984-10       Impact factor: 4.272

5.  5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes.

Authors:  W M Rideout; G A Coetzee; A F Olumi; P A Jones
Journal:  Science       Date:  1990-09-14       Impact factor: 47.728

6.  Presence of a potent transcription activating sequence in the p53 protein.

Authors:  S Fields; S K Jang
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

7.  A multiple cytokine- and second messenger-responsive element in the enhancer of the human interleukin-6 gene: similarities with c-fos gene regulation.

Authors:  A Ray; P Sassone-Corsi; P B Sehgal
Journal:  Mol Cell Biol       Date:  1989-12       Impact factor: 4.272

8.  p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors.

Authors:  A Rogel; M Popliker; C G Webb; M Oren
Journal:  Mol Cell Biol       Date:  1985-10       Impact factor: 4.272

9.  A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family.

Authors:  S Akira; H Isshiki; T Sugita; O Tanabe; S Kinoshita; Y Nishio; T Nakajima; T Hirano; T Kishimoto
Journal:  EMBO J       Date:  1990-06       Impact factor: 11.598

10.  Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.

Authors:  J V Gannon; R Greaves; R Iggo; D P Lane
Journal:  EMBO J       Date:  1990-05       Impact factor: 11.598

View more
  107 in total

1.  Inhibition of interleukin-6 promoter activity by the 24 kDa isoform of fibroblast growth factor-2 in HeLa cells.

Authors:  I Delrieu; J C Faye; F Bayard; A Maret
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

2.  Conditional ablation of Ikkb inhibits melanoma tumor development in mice.

Authors:  Jinming Yang; Ryan Splittgerber; Fiona E Yull; Sara Kantrow; Gregory D Ayers; Michael Karin; Ann Richmond
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

3.  Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase.

Authors:  D Lin; M T Shields; S J Ullrich; E Appella; W E Mercer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

4.  Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding.

Authors:  E Shaulian; A Zauberman; D Ginsberg; M Oren
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

5.  Mutation of the casein kinase II phosphorylation site abolishes the anti-proliferative activity of p53.

Authors:  D M Milne; R H Palmer; D W Meek
Journal:  Nucleic Acids Res       Date:  1992-11-11       Impact factor: 16.971

6.  Repression of the basal c-fos promoter by wild-type p53.

Authors:  N Kley; R Y Chung; S Fay; J P Loeffler; B R Seizinger
Journal:  Nucleic Acids Res       Date:  1992-08-11       Impact factor: 16.971

7.  Nuclear factor κB inhibition reduces lung vascular lumen obliteration in severe pulmonary hypertension in rats.

Authors:  Daniela Farkas; Aysar A Alhussaini; Donatas Kraskauskas; Vita Kraskauskiene; Carlyne D Cool; Mark R Nicolls; Ramesh Natarajan; Laszlo Farkas
Journal:  Am J Respir Cell Mol Biol       Date:  2014-09       Impact factor: 6.914

Review 8.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

9.  Mouse p53 represses the rat brain creatine kinase gene but activates the rat muscle creatine kinase gene.

Authors:  J Zhao; F I Schmieg; D T Simmons; G R Molloy
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

10.  Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53.

Authors:  C Kunz; S Pebler; J Otte; D von der Ahe
Journal:  Nucleic Acids Res       Date:  1995-09-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.